-
Mubritinib–HSA Binding: Mechanism and Implications
2026-08-17
This study combines multispectroscopic measurements, biochemical assays, and molecular docking to define how mubritinib binds human serum albumin. Its key contribution is linking moderate site-I binding and static fluorescence quenching to measurable changes in albumin structure and esterase-like function, providing a mechanistic basis for interpreting mubritinib disposition.
-
Calpain Inhibitor II, ALLM: From Protease to Pathway
2026-08-16
A mechanistic and translational framework for using Calpain Inhibitor II, ALLM to interrogate calpain–FAK proteolysis, apoptosis, and protease-driven cancer phenotypes without confusing pathway evidence with therapeutic validation.
-
PreScission Protease (PSP) for Tag Cleavage
2026-08-14
PreScission Protease (PSP) is an HRV 3C protease fusion enzyme for removing compatible affinity tags from recombinant proteins at low temperature. It should be used only when the defined recognition sequence is present and accessible; it is not a suitable broad-spectrum protease for substrates lacking the cleavage site.
-
Bradykinin BA5201: Practical Assay Guide
2026-08-14
Bradykinin BA5201 provides a defined research peptide for studying endothelium-dependent vasodilation, vascular permeability modulation, smooth muscle contraction, pain mechanisms, and inflammation signaling. It is intended for controlled scientific workflows only, not for diagnostic, therapeutic, or medical use, and solutions should be prepared for prompt use rather than long-term storage.
-
Belinostat (PXD101) Workflow for Cancer Research
2026-08-13
Belinostat (PXD101) supports reproducible pan-HDAC inhibition studies in bladder and prostate cancer models, with complementary proliferation, chromatin, and cell-death readouts. This workflow uses time-resolved measurements to distinguish cytostatic growth arrest from true killing and to improve interpretation of dose-response data.
-
Mutational Drivers and Drug Resistance in Myeloma Cells
2026-08-13
Vikova et al. provide the first comprehensive exome-wide characterization of a large, molecularly diverse panel of human multiple myeloma cell lines, identifying established and potentially novel drivers of disease biology. By connecting recurrent mutations and pathway alterations with drug-response phenotypes, the study offers a practical framework for model selection in hematological malignancy research.
-
Shufeng Xingbi Therapy in Allergic Rhinitis Rats
2026-08-12
This preprint examines how Shufeng Xingbi Therapy affects allergic rhinitis in rats by integrating nasal inflammation, Th1/Th2-associated signaling, intestinal microbiota, and short-chain fatty acids. Its main contribution is a gut–nasal immune framework, although the preclinical design does not yet establish whether microbiota changes directly cause the observed therapeutic effects.
-
Indole-3-pyruvic Acid: A Translational Metabolite
2026-08-12
Indole-3-pyruvic acid, or IPA, is emerging as more than an auxin biosynthesis intermediate. Its position at the intersection of tryptophan metabolism, AhR-mediated immune modulation, and UHRF1–AMPK signaling gives translational researchers a practical framework for connecting plant hormone research, rheumatoid arthritis research, and cancer immunometabolism.
-
HATU: From Coupling Chemistry to Inhibitor Design
2026-08-11
HATU links precise carboxylic acid activation with modern peptide synthesis chemistry and medicinal chemistry. This guide explains how its reaction logic, handling, and assay-aware workflow support the construction and evaluation of selective enzyme inhibitors.
-
Epalrestat: Aldose Reductase Inhibitor Workflows
2026-08-11
Epalrestat gives researchers a practical way to connect polyol pathway inhibition with oxidative stress, diabetic neuropathy, and emerging cancer-metabolism questions. This guide combines formulation details, assay-ready protocol parameters, pathway controls, and troubleshooting for more interpretable experiments.
-
HATU Workflows for Selective Inhibitor Synthesis
2026-08-10
Learn how HATU streamlines carboxylic acid activation, peptide synthesis chemistry, and late-stage analog assembly for challenging amide and ester formation. This practical workflow connects reaction setup and troubleshooting with the stereochemical, structural, and biochemical priorities highlighted in selective IRAP inhibitor discovery.
-
Structural Tuning of CD38 CAR Binders
2026-08-09
Cheng et al. dissected how the CD38-targeting CAR binders RP02 and 028 recognize the antigen, inhibit its enzymatic function, and influence CAR-T behavior. Their structures and functional assays show that epitope geometry and calibrated affinity—not affinity alone—can help reduce fratricide while preserving antitumor cytotoxicity.
-
Disulfiram in Precision Cancer Research
2026-08-08
Disulfiram supports complementary ALDH2, ROS, apoptosis, and proteasome workflows rather than a single readout. This guide translates its solubility, dosing, and model-specific evidence into reproducible cancer research experiments, with practical troubleshooting for cell-based and purified-proteasome assays.
-
v-Aga-IVA Reveals Low-Affinity N-Type Ca Blockade
2026-08-07
Sidach and Mintz revisited the pharmacological separation of P-, Q-, and N-type calcium channels by testing v-Agatoxin-IVA in native rat neurons. Their results show that micromolar toxin concentrations can incompletely inhibit N-type currents through a voltage-dependent gating effect, limiting the toxin’s use as a selective Q-type channel probe.
-
Thiazovivin (A5506): Technical Guidance for ROCK Inhibition
2026-08-07
Thiazovivin is a high-purity ROCK inhibitor optimized for enhancing induced pluripotent stem cell generation and improving human embryonic stem cell survival after dissociation. It is best deployed within rigorously controlled stem cell research workflows, with limited application beyond this context due to the specificity of its validated use cases.